$LFST

TPG GP A, LLC sold $144.9M of LFST (indirect holdings)

TPG GP A, LLC sold 13,643,207 indirectly-held shares of LifeStance Health Group, Inc. (LFST) at $10.62 ($144.89M total) on 2026-08-10.

Original reporting
SEC EDGAR · TPG GP A, LLC
Published Aug 12, 2026, 9:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LFST
Neutral
low confidence
Mentioned
$LFST
Relevance
8/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LFSTNeutralLow
01

Why it matters

A 10% owner sold $144.89M of LFST shares indirectly, which can influence short-term sentiment but does not provide new operating or financial guidance.

02

Market read

Traders may monitor for follow-on selling pressure or additional insider filings, but the disclosure alone is not a fundamental catalyst.

03

What to watch

The text does not specify tax, diversification, or financing needs, and it provides no 10b5-1 plan details beyond stating none; without context, interpreting intent is speculative.

Relevance 8/10Novelty 5/10Timing: filed 2026-08-12, sale dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for LifeStance Health Group, Inc. (LFST).

Company-level read

Ticker impact

$LFSTNeutralLow confidence
Context

TPG GP A, LLC, a 10% owner, sold 13,643,207 LifeStance Health shares in an open-market transaction worth $144.89M on 2026-08-10.

Expected impact

Mild negative bias for the next few sessions, with limited follow-through unless additional disclosures emerge.

Evidence & confidence

The filing is a Form 4 insider transaction with no 10b5-1 plan and no accompanying company-specific operational or guidance change in the text.

Market effects

No sector-level implications are disclosed; this is company-specific ownership activity.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity management by a large holder and may not reflect negative fundamentals, especially since the transaction is open-market and not tied to a company event here.

Key entities

  • LifeStance Health Group, Inc.

    Subject of the Form 4 insider transaction disclosure (LFST).

  • TPG GP A, LLC

    Reporter of the indirect open-market sale of LFST shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LFSTMedAI 8/10

LifeStance Health Group, Inc. Q2 2026 Earnings Call Summary

LifeStance Health Group reported Q2 2026 revenue growth of 26%, driven by higher visit volumes and a 6% rise in revenue per visit, and said visits per clinician rose 7% YoY. The company raised full-year 2026 guidance to $1.685B-$1.725B revenue and 13.2% adjusted EBITDA margins, approved a new $100M buyback, and reported Q2 free cash flow of $88M.

$LFSTHighAI 9/10

LifeStance (LFST) Q2 2026 Earnings Call Transcript

LifeStance (LFST) reported Q2 2026 results on an earnings call. Revenue rose to $435 million (+26%) on 2.6 million visits (+19%) and total revenue per visit of $167 (+6%). Adjusted EBITDA was $66 million (+94%) with a 15.2% margin. Full-year 2026 revenue guidance was raised to $1.685-$1.725 billion and adjusted EBITDA to $215-$235 million.